WCG Names Donna Snyder Executive Physician

WCG, a company that provides clinical research services, has appointed Donna Snyder, Executive Physician. Snyder’s extensive experience and leadership in clinical research, including over a decade with the U.S. Food and Drug Administration (FDA), will increase WCG’s expertise and capabilities to accelerate and advance clinical trials.

Snyder will play a pivotal role in collaborating with clients and stakeholders across WCG’s business units. With her training in pediatrics, bioethics, and product and drug development, she brings invaluable expertise gained during her tenure with the FDA and as a practicing physician.

Snyder is an expert in applying scientific and ethical regulations related to the inclusion of children in clinical research and the development of pediatric products. She has co-authored numerous books and publications, solidifying her position as a respected thought leader in her field.

“We are thrilled to welcome Dr. Snyder to WCG,” said Sam Srivastava, CEO, WCG. “Dr. Snyder’s expertise in drug development and ethical considerations will further strengthen the partnership and solutions WCG offers our clients to support their goals to be more efficient and effective throughout their trials. Her focus on patient-centric care and how it relates to enhanced clinical outcomes will undoubtedly benefit our clients and the patients they serve.”

“I’m delighted to join the exceptionally talented, mission-driven team at WCG,” said Snyder. “Additionally, the company’s commitment to innovation in clinical research is inspiring. I look forward to playing a role in helping to accelerate clinical research for our clients, while upholding the ethical standards for which WCG is known.”